Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results

American Journal of Hematology
Felicetto FerraraGiuseppina Mele

Abstract

The strategy named double induction (DI) in acute myeloid leukemia (AML) consists of two courses of chemotherapy irrespective of the degree of cytoreduction in the bone marrow (BM) after the first course, unless severe complications prohibit its application. We describe treatment results from a series of 33 patients in whom DI was adopted only after demonstration of persistence of more than 10% blast cells at day 15 (D15) examination of BM. All patients received as induction idarubicin, cytarabine, and etoposide. As second induction, we administered the combination of fludarabine, intermediate dose cytarabine, and Granulocyte colony stimulating factor (G-CSF). The median blast count at D15 was 30 (15-90). Overall, 30 of 33 patients were judged as eligible to receive DI, reasons for exclusion being in all cases active infection in the context of severe pancytopenia. Nineteen patients (63%) had unfavorable karyotype and 11 (37%) normal karyotype; seven of these had Fms-like tyrosine kinase gene internal tandem duplication (FLT3/ITD) mutation. Overall, complete remission (CR) was achieved in 20/30 patients (67%), while eight patients (27%) were refractory and two died of infectious complications. All refractory patients had unfavo...Continue Reading

References

Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F FerraraF Lo Coco
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jul 3, 2004·The Lancet Oncology·Felicetto Ferrara
Aug 22, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Felicetto FerraraFabrizio Pane
Nov 13, 2007·Critical Reviews in Oncology/hematology·Felicetto FerraraFranco Leoni
May 26, 2009·Experimental Hematology·Joshua L Shipley, James N Butera
Jun 11, 2009·JAMA : the Journal of the American Medical Association·Carolyn J HildrethRichard M Glass
Jul 7, 2009·Hematology/oncology Clinics of North America·Amy Heerema-McKenney, Daniel A Arber
Aug 15, 2009·Current Oncology Reports·Amir T Fathi, Judith E Karp
Sep 23, 2009·Current Opinion in Oncology·Brunangelo FaliniMaria Paola Martelli
Sep 25, 2009·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
Sep 25, 2009·The New England Journal of Medicine·Hugo F FernandezMartin S Tallman
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franco MandelliTheo de Witte
Dec 8, 2009·Cancer Genetics and Cytogenetics·Marina TarsitanoLaura Vicari
Dec 25, 2009·The New England Journal of Medicine·Harris V K NainaSamar Harris
Feb 23, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Felicetto FerraraSalvatore Palmieri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.